A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
This phase 2 study will determine the antitumor activity, based on the objective rate, of
oral MKC-1, administered twice daily for 14 consecutive days every 4 weeks, in patients with
advanced or metastatic breast carcinoma. The study will also evaluate the safety and response
duration in patients, time to tumor progression, and overall survival in patients following
MKC-1 therapy.